|
gptkbp:instanceOf
|
gptkb:nonsteroidal_anti-inflammatory_drug
|
|
gptkbp:affiliatedWith
|
propionic acid derivatives
|
|
gptkbp:ATCCode
|
M01AE01
|
|
gptkbp:brand
|
gptkb:Nurofen
gptkb:Motrin
gptkb:Advil
|
|
gptkbp:CASNumber
|
15687-27-1
|
|
gptkbp:chemicalFormula
|
C13H18O2
|
|
gptkbp:contraindication
|
gptkb:peptic_ulcer
hypersensitivity to NSAIDs
severe heart failure
|
|
gptkbp:countryOfOrigin
|
gptkb:United_Kingdom
|
|
gptkbp:developedBy
|
gptkb:Boots_UK
|
|
gptkbp:discoveredBy
|
gptkb:John_Nicholson
gptkb:Stewart_Adams
|
|
gptkbp:discoveredIn
|
1961
|
|
gptkbp:eliminationHalfLife
|
2-4 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:FDAApproved
|
1974
|
|
gptkbp:interactsWith
|
gptkb:warfarin
gptkb:aspirin
gptkb:methotrexate
lithium
|
|
gptkbp:IUPACName
|
(RS)-2-(4-(2-methylpropyl)phenyl)propanoic acid
|
|
gptkbp:KEGGID
|
D00126
|
|
gptkbp:legalStatus
|
over-the-counter
prescription (higher doses)
|
|
gptkbp:marketedAs
|
1969
|
|
gptkbp:mechanismOfAction
|
COX inhibitor
|
|
gptkbp:meltingPoint
|
76°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US, prior to 30 weeks gestation)
D (US, after 30 weeks gestation)
|
|
gptkbp:PubChem_CID
|
gptkb:DB01050
gptkb:CHEMBL521
3672
3546
|
|
gptkbp:riskFactor
|
cardiovascular events (with prolonged use)
kidney damage (with prolonged use)
|
|
gptkbp:routeOfAdministration
|
oral
topical
intravenous
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
gastrointestinal upset
increased risk of bleeding
|
|
gptkbp:solubility
|
poor
|
|
gptkbp:UNII
|
WK2XYI10QM
|
|
gptkbp:usedFor
|
pain relief
fever reduction
inflammation reduction
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:IAZDPXIOMUYVGZ-UHFFFAOYSA-N
gptkb:Domestic_cats
gptkb:PEDCQBHIVMGVHV-UHFFFAOYSA-N
gptkb:Pyrexia
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ibuprofen
|